A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non- Hodgkin Lymphoma

  • Si Lun Tam, Con (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date17/07/2316/07/25

Keywords

  • Clinical trial
  • Non-hodgkin lymphoma